Skip to content
DataLookout
Start free
Menu

NCT05229341

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

See at-risk trials from City of Hope Medical Center

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 3 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 22, 2026 to Jan 21, 2027
  2. Start date: Oct 22, 2021 to Dec 23, 2021
    • Eligibility criteria expanded, about 5 words
    • Study description revised
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Sensitivity of Diagnostic Deoxyribonucleic Acid (DNA) Methylation Signatures (DDMS-2)
Timeframe: Up to 5 years
Specificity of DDMS-2
Timeframe: Up to 5 years
Positive predictive value (PPV) of DDMS-2
Timeframe: Up to 5 years
Negative predictive value (NPV) of DDMS-2
Timeframe: Up to 5 years

Arms and interventions

Diagnostic (needle biopsy, DDMS-2)Experimental

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Procedures: Diagnostic Procedure, Needle Biopsy

Other: Electronic Health Record Review

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States